07:00 , Sep 22, 2014 |  BioCentury  |  Strategy

Weighing in on obesity

Contrave naltrexone/bupropion will be the first new obesity drug launched in the past two years to have the full weight of a large pharma partner with an established commercial footprint in the cardiometabolic space behind...